Last reviewed · How we verify
NCT02715843
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
trial testing MT-3724 in Non-Hodgkin's B-cell Lymphoma. No longer available.
Quick facts
| Lead sponsor | Molecular Templates, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 3 locations across United States |
Drugs / interventions tested
- MT-3724 — full drug profile →
Conditions studied
- Non-Hodgkin's B-cell Lymphoma — all drugs for Non-Hodgkin's B-cell Lymphoma →
Sponsor
Molecular Templates, Inc. — full company profile →
Who can join
18 and older, any sex, with Non-Hodgkin's B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an active treatment, extended access study open solely to those subjects who have successfully completed the Core and Repeat Dosing portions of the MT-3724\_NHL\_001\_US clinical study and who, in the investigator's judgment, (i) have not had progressive disease while on MT-3724 treatment (i.e.; have shown a complete or partial response or stable disease), (ii) have experienced no clinical or laboratory toxicities that would contraindicate further MT-3724 dosing and (iii) have no acceptable and better alternative treatment available to them.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02715843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MT-3724
Trials testing the same drug.
- NCT03645395 — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for t · Phase 2 · terminated
- NCT03488251 — PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of · Phase 2 · terminated
Other Molecular Templates, Inc. trials
Trials by the same sponsor.
- NCT06034860 — Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types · Phase 1 · terminated
- NCT04795713 — Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 · Phase 1 · terminated
- NCT04017130 — A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated
- NCT04029922 — Study of MT-5111 in HER2-positive Solid Tumors · Phase 1 · terminated
- NCT03645395 — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for t · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02715843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Molecular Templates, Inc.
- Last refreshed: 11 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02715843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing